Presenting Companies
Oncology Investors Conference
December 7-10, 2021


Advanced Microbubbles drug delivery platform aims to solve a well-known major challenge in medicine of getting drugs through the tumor barrier and across the blood brain barrier. It uses stabilized microbubbles, which are agitated with ultrasound at the site of a tumor, to open up the barriers so drugs can enter in a precise and noninvasive manner. It also enables drug efficacy at doses that will reduce or eliminate overall side-effects to the cancer patient. These ultrasound triggered microbubbles can be delivered alongside most drug classes including chemotherapy, gene therapy, immunotherapy or nanoparticle drugs.


Altamira Therapeutics is dedicated to developing therapeutics that address important unmet medical needs. The Company is currently active in three areas: the development of RNA therapeutics for extrahepatic therapeutic targets (OligoPhoreTM / SemaPhoreTM platforms; preclinical), nasal sprays for protection against airborne viruses and allergens (BentrioTM; commercial) or the treatment of vertigo (AM-125; Phase 2), and the development of therapeutics for intratympanic treatment of tinnitus or hearing loss (Keyzilen® and Sonsuvi®, Phase 3). The Company was founded in 2003 and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Altamira Therapeutics Ltd. trade on the NASDAQ Capital Market under the symbol “CYTO.”


AmMax is a private clinical-stage biotech company founded in March 2020 to develop therapies under an exclusive worldwide license from Amgen, Inc. that leverage the diverse and critical roles played by the colony stimulating factor 1 receptor (CSF1R) signaling pathway for macrophage-driven diseases in multiple organ systems. AmMax has two clinical stage programs using AMB-05X, its proprietary CSF1R monoclonal antibody platform. The company is enrolling patients in a Phase 2 clinical program for tenosynovial giant cell tumor (TGCT), and is preparing to initiate a Phase 2 clinical study in idiopathic pulmonary fibrosis (IPF) in early 2022. Both represent diseases with significant unmet medical needs and sizable market potential.


Atrin Pharmaceuticals is an oncology company with a pipeline of drug candidates focusing on synthetic lethality by targeting DNA Damage and Response. Lead program, ATR inhibitor, has been IND approved and a second program is ready to enter IND enabling studies. Atrin also have three proprietary and integrated platform technologies to support discovery and advance development.


AIVITA Biomedical is a platform vaccine company with clinical-stage programs in cancer and COVID-19. Our unique expertise in stem cell growth and directed, high-purity differentiation enables us to develop safe, efficient and economical manufacturing processes for therapeutic development.


Bexion is a clinical-stage biopharmaceutical company whose lead drug candidate, BXQ-350, represents a new generation of immunotherapy. BXQ-350 was designed to impact lysosomal sphingolipid metabolism, and hence imparts both innate and adaptive immune activity, as well as directly induce tumor cell death. BXQ-350 also targets enzymatic and GPCR targets that are involved in multiple CNS diseases and peripheral neuropathy.


Biocept, Inc. (Nasdaq: BIOC) develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information to aid in the diagnosis, treatment and monitoring of patients with cancer. In addition to its broad portfolio of blood-based liquid biopsy tests, the company has developed the CNSide™ cerebrospinal fluid assay, designed to diagnose cancer that has metastasized to the central nervous system. Biocept also is leveraging its molecular diagnostic capabilities to offer nationwide RT-PCR-based COVID-19 testing and services to support public health efforts during this unprecedented pandemic.


BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) is a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer. BriaCell achieved positive proof-of-concept in a Phase I/IIa clinical trial for Bria-IMT™ in patients with advanced breast cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT™ in a combination with retifanlimab and epacadostat (both provided by Incyte under a collaboration agreement). Additionally, BriaCell is developing Bria-OTS™, the first “off the shelf” personalized immunotherapy for advanced breast cancer.


Brooklyn ImmunoTherapeutics (BTX) is a clinical-stage biopharmaceutical company committed to creating a world where patients and families with high unmet medical needs have access to effective treatments. BTX is a pioneer in using the latest technologies such as synthetic mRNA, cellular reprogramming, gene editing, and complex human-derived mixed cytokines. These advances fuel their ongoing programs, including iPSC-derived MSC (iMSC), gene-edited iMSC, and in vivo gene editing. Additionally, they have developed the IRX-2 immuno-therapy, which is approaching the conclusion of its Phase 2B study. The BTX team is diverse in its background and experience, federated around the use of science and technology to advance transformative therapies to meet the needs of patients.

Creatv BIO Logo 8 - BIO - 1.5 inches.jpg

Curadigm, a Nanobiotix SA subsidiary, is an early-stage nanotechnology company dedicated to improving outcomes for patients by shifting the therapeutic delivery paradigm. Curadigm’s Nanoprimer technology is designed to increase drug bioavailability while decreasing unintended off-target effects, specifically liver toxicity. The platform can be used with most intravenous therapeutics across multiple drug classes.


We are developing an approach for human natural killer (NK) cell immunotherapy that involves an off-the-shelf CAR NK cell that enables the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Our NK cell engineering platform builds on Drs. Caligiuri’s and Yu’s 54 years of collective laboratory investigation of NK cells, their treatment of over 1,000 patients with therapies modulating NK cells in man, and their prior success in engineering T cells. Our current platform includes proprietary technologies that enable us to (1) generate an abundant supply of potent human CAR NK cells to treat multiple patients from a single umbilical cord blood product, (2) highly effective transduction efficiency of the CAR into the human NK cells, (3) improved the persistence of these CAR NK cells for sustained activity once infused into the body, (4) an ability to freeze, store and thaw our engineered NK cells for infusion into unmatched cancer patient recipients for an off-the-shelf treatment of cancer.


Sales are to start in 2022 of our cancer screening test that identifies a marker that is present not only in tumors, but precancerous tissue as well, which enables us to identify patients at the EARLIEST stages, even before the cancer has formed. Early-stage tumors can be small and so our advantage over imaging tests, such as mammograms, CTs, etc., is that we do not need tumors to be a certain size. This is much more than a concept, as over 20 clinical trials in 7 countries have been published with over 10,000 patients that have demonstrated outstanding accuracy, with sensitivity and specificity rates typically ranging from 80% to 95%. The screen is safe, inexpensive, easy to conduct in an office with no equipment needed and only takes 15 minutes. We expect our test to have a dramatic reduction in cancer mortality.


ExoProTher Medical is a preclinical stage company developing a first in class acellular therapeutic platform targeting cancers with mutation in gene TP53 - the most frequently observed genetic alteration in human cancer.


Felicitex Therapeutics is a drug discovery company at the forefront of one of the most promising areas in oncology – quiescent (sleeping) cancer cells. We are developing treatments and diagnostic assays to improve the effectiveness and long-term outcomes of treatments for the deadliest and most resistant to therapy cancers: pancreatic, colorectal, non-small cell lung, and ovarian.


Geneius is a 4th generation T cell company for the treatment of hematological and solid tumors. Geneius’ autologous T cell products are designed to be administered first-line, as outpatient therapy by the local community oncologist ready when the patient needs to be treated via two 30 minute infusions. The company’s T cell products solve the challenges associated with CAR T and allogeneic CAR T in lymphoma and TILs in lung cancer and other solid tumors. In addition to the best T cells in the business and a robust low-cost closed system manufacturing T cell manufacturing platform, Geneius has a strong IP position, and the management and the scientific team experienced in leading T cell companies.


GeoVax Labs, Inc. (Nasdaq: GOVX) is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer using two novel patented platforms (GV-MVA-VLP™ and Gedeptin®). An FDA-funded Phase 1/2 clinical trial is currently enrolling to evaluate the safety and efficacy of Gedeptin therapy in patients with recurrent head and neck squamous cell carcinoma (HNSCC). GeoVax’s MVA-VLP cancer immunotherapy program is based on the concept of combining a tumor-associated antigen vaccine with an Immune Checkpoint Inhibitor (“ICI”), with the goal of achieving regression of tumor growth. The initial animal studies, based upon a GeoVax-MUC1 vaccine/ICI combination, have been encouraging and additional studies are being planned.


IMPACT Therapeutics is a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality. IMPACT Therapeutics has assembled one of the most comprehensive DNA damage response (DDR) global pipeline of novel drug candidates generated by in-house discovery efforts and is expanding to other novel synthetic lethality targets to broaden its pipeline. The lead clinical program, PARP inhibitor (senaparib/ IMP4297), is in Phase II/III studies for ovarian cancer, prostate cancer, small cell lung cancer and other indications worldwide, including China. Phase I study of Wee1 inhibitor (IMP7068) is conducted globally. ATR Inhibitor IMP9064 has received IND Clearance by FDA to start clinical studies in the U.S. and Hedgehog pathway inhibitor (IMP5471) has received IND approval from NMPA to initiate clinical studies in China.


Immunicom combines advancement in molecule development with a unique therapeutic delivery approach, providing safe and effective solutions for critical conditions such as cancer, auto-immune diseases, renal, and inflammatory diseases. We inhibit disease growth without using drugs and associated toxic side effects by targeted removal of cytokines and other soluble factors that suppress a natural immune response. Our first area of focus is oncology and Immunicom has received initial approval in Europe for advance refractory Triple Negative Breast Cancer (TNBC) through a CE Mark and has been classified by the FDA as a Breakthrough Technology. We are working toward a soft commercial launch in various European countries, along with Israel and Turkey, by Q4 2021. We expect initial FDA approval by late 2022, early 2023. We have raised $32M to-date from high net-worth individuals and family offices through Series A and Series B rounds of funding. We are currently raising $23M in a Bridge round, $8M of which has already been secured through our existing investor base.

Infinitum Health - Logo.jpg

Infinitum Health, LLC was created to deliver high quality Integrative Medicine products, using biotechnology and bioengineering methods. Our flagship products, Infinimin® (Immunity Supplement), Infiniderm® (Daily Youth Lotion), and ReLeaf® (Pain Reliever) combine a base formulation with additional organic extracts proven with evidence-based research for their anti-tumor, anti-viral, anti-inflammatory, skin health promotion, natural UV sun block, and natural pain relief. Infinitum Health uses a trade-secret mathematical engineering model to design its products based on current research evidence available. Infinitum Health's goal is to have strong evidence-based research behind every product to help support its use, further its research, and expand its reach across the world to enhance population health.


Kintara is a biopharmaceutical company focused on the development of new solid tumor cancer therapies. Located in San Diego, California, Kintara is dedicated to the development of novel cancer therapies for patients with unmet medical needs. Kintara is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for Cutaneous Metastatic Breast Cancer (CMBC).


KisoJi is an antibody company that is revolutionizing the discovery and development of antibody therapeutics. Its antibody platform includes a multi-species VHH single domain antibody transgenic mouse, an AI-enabled antibody paratope fingerprinting and search capability, and a robust, easily manufacturable multi-specific antibody format. From this platform, the company has developed a preclinical pipeline that includes a naked TROP2 antibody with significant anti-tumor effects (including tumor regression) in solid tumor models without the need for a drug conjugate. The company also has a preclinical tri-specific antibody for neuroendocrine tumors which causes prolonged survival in SCLC xenograft models.


Maxwell Biosciences is a preclinical stage drug platform company partnering with large pharma companies to develop an entirely new class of patented small molecule drugs that destroy SARS-CoV-2, the COVID virus, and other viruses. This world-first drug class called Maxwell’s PeptoidsTM mimics natural human immune system antimicrobial peptides.  Maxwell Biosciences recently announced confirmation by US Govt-funded labs that Maxwell's lead drug candidate has direct virucidal action against Herpes virus and SARS-CoV-2, the COVID-19 virus. Additionally, recent live mouse safety data at Texas A&M show Maxwell's drugs benefit from a tissue-safe toxicology profiles. These findings support the expected safety and effectiveness of Maxwell's “multi-asset, multi-target” virucidal drug platform. Maxwell's drug platform is supported by a granted patent portfolio and is strongly positioned in the fight against emergent viral pandemics. Maxwell is raising funds for advanced preclinical and human trials.


Monopteros Therapeutics is a clinical-stage biotechnology company developing a first-in-class inhibitor of MALT1 protease. The company’s first asset MPT-0118, is conducting a phase 1 clinical trial to investigate reprogramming regulatory T cells in solid tumors.


Nammi Therapeutics is a pre-clinical immuno-oncology with two proprietary platforms that focus an immune response on anti-tumor activity while reducing systemic toxicities. Masked immuno-cytokines (MICs) provide layered protective mechanisms while maintaining the full power of cytokine activity within tumors. Nammisomes focus activity of proprietary immuno-modulating prodrugs at the tumor site.


Neosoma is a neuro-oncology SaaS-based care management platform powered by proprietary AI-driven MRI tumor analysis modules. Our interoperable suite of capabilities provides centralized, longitudinal disease analysis, combining treating team workflow and tumor board capabilities with novel empirical disease insights to aid in faster, more accurate, and more confident treatment decisions. Neosoma’s tumor analysis modules are utilized in clinical trials to standardize and accelerate the segmentation and longitudinal measurement of brain tumors.


NuvOx Pharma is a clinical stage pharmaceutical company developing a drug that improves the flow of oxygen from lungs to blood and from blood to tissue. Over 30 animal studies have shown therapeutic effect in seven different indications. Phase Ib/II clinical trials in stroke and oncology demonstrated safety and evidence of efficacy, and the company is preparing to run a trial in COVID-19 patients with Acute Hypoxemic Respiratory Failure (AHRF).


OncoOne is a preclinical stage biotech based in Vienna, Austria, focused on advancing novel therapies targeting the macrophage migration inhibitory factor, or MIF, to the clinic in 2023. MIF has been well characterized for over 50 years as a proinflammatory cytokine implicated in acute and chronic inflammatory conditions. In cancer, MIF is associated with high tumor burden, increased metastatic potential, and poor prognosis by driving tumorigenic cell signaling and exerting immunomodulatory activities, which contribute to immune evasion. OncoOne’s founders discovered that at sites of inflammation – such as a nephritic kidney, and inflamed colon, or a solid tumor -- MIF aggregates and undergoes a confirmational change, becoming the disease-related isoform of MIF, named oxidized MIF or oxMIF by OncoOne’s founders in 2015. By targeting oxMIF, OncoOne’s therapies counter-act the tumorigenic and inflammatory activities of MIF and will be tested clinically with the goal of improving outcomes in patients with solid tumors and autoimmune disorders.


Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the development, manufacture, and commercialization of complex and innovative treatments for patients battling cancer and other life-threatening diseases.


Propella Therapeutics is a private, clinical-stage oncology company with novel lymphatic system methodology that enables its patented, internally invented therapies to be delivered directly to targeted tissues, avoiding first-pass liver safety and metabolic effects. Lead candidate, PRL-02 (abiraterone decanoate, composition of matter protection into 2040), is a CYP17 lyase inhibitor currently being developed (Phase 1/2a) as a potential best-in-class treatment for metastatic prostate cancer and has first-in-class potential for additional cancer indications beyond advanced prostate. PRL-02 is administered as a long-acting (3-month) intramuscular depot injection designed to circumvent the safety and efficacy shortcomings and patient adherence challenges of oral Zytiga® (abiraterone acetate), the only androgen biosynthesis inhibitor approved for the treatment prostate cancer. PRL-02 is positioned for a large and growing androgen receptor pathway-directed, prostate cancer therapy market opportunity which is expected to grow from $6.3 billion in 2020 to $17.4 billion in 2029. Propella has been entirely funded by a private family office and is initiating its first outside financing round.

Propelle Therapeutics - Logo.png

Propelle Therapeutics (PTX) is focused on developing critical, anti-tumorigenic cytokine immune checkpoint inhibitors that are modified for improved and sustained solid tissue tumor uptake and designed for exogenous administration without increasing accumulation in non-target tissues. Effort is directed to multi-functional approaches either as monotherapy, or combinations with other I/O and non-I/O therapies, including our pipeline programs, which can be used in the Tumor Microenvironment (TME) to rebalance the immune system.


Qu Biologics is a Phase 2 clinical stage biotech company with a novel transformative immunotherapy platform, Site Specific Immunomodulators (SSIs). SSIs are uniquely positioned in oncology since, unlike single-target drugs, SSIs restore all the important cells and anti-cancer immune pathways in a targeted organ, including NK cells, M1 macrophages and activated adaptive immune cells, upregulation of the NKG2D pathway and down-regulation of multiple important check-point inhibitors in a manner aligned with the body’s natural anti-cancer mechanisms. Qu has compelling clinical data from four completed Phase 2 studies with a very good safety profile in the more than 360 patients treated to date. With a very good safety profile, synergy and broad applicability across a wide range of cancers, Qu is seeking VC funding and Pharma partnership to accelerate the development of Qu's first-in-class SSI platform in oncology.


Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. The company has a pipeline of four distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical stages of development from some of the world’s leading universities and institutes. The pipeline has been built based on the potential to be First to Market or Best in Class. The clinical program includes five Phase 2 and two Phase 1 trials in a variety of solid tumor cancers including breast, kidney and brain, with a total of 133 patients dosed to date. To realise this potential, Radiopharm has formed a world class management team recruited from some of the most prestigious radiopharmaceutical companies and universities globally. The CEO Riccardo Canevari, was until recently, the Chief Commercial Officer at Novartis’ Advanced Accelerator Applications one of the world’s leading radiopharmaceutical companies and the Chief Medical Officer, Professor David Mozley, was until recently, Professor of Nuclear Medicine at the prestigious Cornell University in New York. The board comprises experienced and seasoned life science-focused Directors with prior radiopharmaceutical and biotech experience.


Rakovina Therapeutics Inc. (TSX-V:RKV) was established in 2020 to develop new cancer treatments based on novel DNA-damage response technologies. Through its collaborative research agreement with the University of British Columbia (UBC), the company is currently conducting lead optimization studies around three patented classes of novel drug candidates. All research is conducted at UBC’s state of the art facilities under the direction of Prof. Mads Daugaard, Rakovina Therapeutics president and UBC faculty member who is a recognized leader in the DDRi field.


Revere Pharmaceuticals is an oncology focused, Boston based biotechnology company leading the development of small molecule therapeutics targeting Rac1 signaling for cancers with unmet clinical need. Rac1 is an unexploited, elusive cancer target and a key driver of tumor growth, metastatic progression, and drug resistance in diverse cancer types. Revere has developed a proprietary high throughput platform that enables us to identify inhibitors of Rac1 activation. Our most advanced program is focused on tumors with Rac1 overexpression with demonstration of excellent anti-cancer activity in preclinical models of breast and prostate cancer. IND filing is expected in 2023.


RubrYc is forging a new path for information-driven discovery of epitope-targeted drug candidates. RubrYc deploys our artificial intelligence and molecular engineering capabilities in the ELS System:


Most cancer patients lack actionable driver mutations or other bio-markers. Thus, most cancer patients receive chemotherapy, which is still a hit or miss experiment today. SageMedic’s has developed its genome-free SAGE Direct Platform™, which will help the millions of cancer patients who don’t have a driver-mutations to identify the treatment that’s most effective for them. This redefines precision medicine and we believe that the impact of our SAGE Direct Platform™ is considerably bigger than that of any new drug under development.


SciTech Development is a clinical stage, biopharmaceutical company that has developed a proprietary nano delivery system (SciTech Drug Delivery Vehicle - SDV) to enable intravenous (IV) delivery of water insoluble (hydrophobic) drugs. One such challenged drug is fenretinide, our lead API, has been shown in numerous clinical trials to be a safe and effective anticancer therapy with targeted cancer destroying activity. The patented combination of the new SDV and fenretinide has led to SciTech’s first drug product ST-001 nanoFenretinide that holds the promise of improving and saving many lives. SciTech’s lead compound ST-001 nanoFenretinide is a small molecule immune oncology nanoFenretinide cancer drug employing a nanoparticle suspension for IV administration comprised of fenretinide in a patented combination with carefully selected phospholipids (inactive ingredients). The phospholipids comprising ST-001 nanoFenretinide were chosen because of their extensive in humans and are recognized as safe for IV use by the FDA.


Silenseed is a clinical stage biopharmaceutical company that is developing proprietary RNA interference (RNAi)-based cancer drugs and delivery systems designed to effectively penetrate and treat malignant solid tumors. The company’s novel drugs, used together with the new delivery system, the LODER™ (LOcal Drug EluteR), have the potential to be one of the most highly effective treatments for solid tumor cancers. Diseases that currently are included in the company’s pipeline are pancreatic cancer, prostate cancer and certain brain cancers.


7HP349 is a first-in-class, clinical-stage oral small molecule that selectively activates the integrins LFA-1 and VLA-4, homing molecules required for effective lymphocyte recruitment and trafficking, tumor infiltration/retention, and killing functions. 7HP349 may improve the effectiveness of immune checkpoint inhibitors against solid tumors as well as a broad range of infectious disease vaccines. 7HP349 is the first clinical-stage molecule to emerge from 7 Hills Pharma’s proprietary platform of novel integrin agonists, comprising multiple pipeline compounds from a risk-diversified range of structural classes.


SFA Therapeutics is a clinical stage start-up biotech company developing compounds discovered in human microbiome. This patented and proprietary platform is based on immuno-modulation of inflammatory factors derived from human gut microbiome. The technology is licensed from and supported by research at Temple University in Philadelphia. These products are a unique native immunotherapy platform with activity currently being investigated in cancer, liver, and auto-immune disease.


Siva Therapeutics is developing a safe and effective cancer treatment termed Targeted Hyperthermia™, which generates therapeutic heat within solid tumors using SivaRods™ gold nanorods and a SivaLum™ infrared light device. Targeted Hyperthermia has multiple beneficial effects on tumors, and it is more selective than chemotherapy, less destructive than radiation, and without the risks of surgery. Siva’s initial clinical target is first-line treatment for early to stage 3 colorectal cancer (CRC.) While the 5-year survival rate for CRC is relatively good (~65%), patient quality of life is poor, resulting in a large unmet need. CRC tends to be localized through early stage 4, making it ideal for local interventional treatment. Targeted Hyperthermia for CRC will be a minimally invasive outpatient procedure that addresses an underserved patient segment.


SIWA Therapeutics is a privately held preclinical stage biotechnology company that has a monoclonal antibody that targets and destroys senescent cells. Our current therapeutic focus is on certain rare and fast track diseases, including cancer metastasis and muscle wasting diseases, such as muscular dystrophy. Beyond these indications, senescent cells are causally implicated in a wide variety of diseases including: neurodegenerative diseases; autoimmune conditions, and infectious diseases. SIWA is currently optimizing its lead antibody, SIWA 318, and in parallel, seeking partnerships to advance SIWA 318 and other related technologies to broaden and accelerate its development pipeline.


Targazyme Inc. is a San Diego-based, clinical-stage biopharmaceutical company developing novel enzyme-based platform technologies and products to improve clinical efficacy and cost of care outcomes for cell therapy, immunotherapies for autoimmune diseases and cancer, stem cell transplantation, gene therapy and regenerative medicine. The Company’s clinical-grade fucosyltransferase enzymes and small molecule products (TZ101 and TZ102) are off-the-shelf biologic products used at the point-of-care to treat therapeutic cells immediately before infusion into the patient using a simple procedure that is easily incorporated into existing medical practice. The Company has received worldwide patents, multiple FDA orphan drug designations, has an open investigational new drug application (IND) with multiple ongoing clinical studies and a Phase 3 Special Protocol Assessment (SPA) with the FDA. Targazyme’s fucosylation technology has received numerous medical and scientific awards from institutions such as NIH, NCI, US Treasury, CPRIT, ETF, OCAST, JDRF, Leukemia, Lymphoma Society.


Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics. Transcenta is developing nine therapeutic antibody molecules for oncology and selected non-oncology indications including bone and kidney disorders.


Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics. Transcenta is developing nine therapeutic antibody molecules for oncology and selected non-oncology indications including bone and kidney disorders.


TransCode Therapeutics is an RNA oncology company, created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics. For decades, RNA has been a topic of investigation by the scientific community as a potentially attractive therapeutic modality because it can target any gene and it lends itself to rational and straightforward drug design. RNA-based therapeutics are highly selective to their targets with the potential to make available a broad array of previously undruggable targets in the human genome. To date, use of RNA for therapy has been limited due to three delivery-related challenges: protecting the RNA from being dismantled by the immune system; maintaining stability so the molecule has time to do its job; and penetrating the targeted organs and cells. We believe these challenges have led researchers to focus on other approaches to cancer therapeutics. Our strategy seeks to overcome these delivery challenges by repurposing a particle used in humans extensively for imaging purposes to now deliver synthetic RNA molecules (called oligonucleotides) to cancer cells.

Vivan Therapeutics - Logo.jpg

Vivan Therapeutics offers personalised cancer therapeutics utilising technology developed at the Icahn School of Medicine at Mt Sinai Medical Center.  We employ a proprietary whole animal model that recapitulates an individual’s unique cancer genetics and can identify treatment with precise personalized combinations of FDA-approved drugs including unexpected combinations. Nearly all combinations incorporate non-cancer drugs, making them less toxic and more affordable. We have demonstrated improved patient outcomes in hard-to-treat cases.  We are integrating AI and predictive modeling to enable rapid personalized  treatment recommendations. We help direct the treatment of cancer patients, enabling the rapid identification of combination therapies to treat polygenic diseases, as well as providing our Biopharma partners with patient-relevant models to test novel therapies and combinations.